GENETIC IMMUNIZATION OF HEPATOCELLULAR CANCER

肝细胞癌的基因免疫

• 批准号: 6173273
• 负责人: James S. Economou
• 金额: $ 18.24万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-01 至 2001-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6173273
• 关键词: MHC class I antigen; T lymphocyte; alpha fetoprotein; cellular immunity; combination cancer therapy; cytokine; dendritic cells; disease /disorder model; gene therapy; genetic manipulation; genetically modified animals; hepatocellular carcinoma; human tissue; immune tolerance /unresponsiveness; immunization; laboratory mouse; mass spectrometry; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; neoplastic cell; synthetic peptide; tissue /cell culture; transfection /expression vector

DESCRIPTION: Hepatocellular cancer (HCC), with a global annual incidence of about 1.2 million new cases, represents one of the largest causes of cancer death in the world. Surgery is the only effective treatment and is available to and benefits only a very small minority of patients. No significant advances in the treatment of HCC have been made in the last two decades. Most HCC produce alpha fetoprotein (AFP), a 609 amino acid residue tumor marker. The applicants hypothesize that short AFP peptides, processed and presented by major histocompatibility class (MHC) molecules on the surface of HCC cells, can serve as suitable targets for an effective cell-mediated immune response against this tumor. They hypothesize that the human and murine T-cell repertoires have AFP peptide-responsive T cells that can be clonally expanded and activated under proper conditions. They propose a multipronged strategy with three Specific Aims to test this hypothesis with both murine and human HCC models.

描述：肝细胞癌 (HCC)，全球年发病率为 约 120 万新病例，是癌症的最大病因之一 世界上的死亡。 手术是唯一有效的治疗方法 只有极少数患者可以获得并受益。 不 近两年来，肝癌的治疗取得了重大进展 几十年。 大多数 HCC 产生甲胎蛋白 (AFP)，这是一种 609 个氨基酸残基 肿瘤标志物。 申请人假设，经过加工的短 AFP 肽 并由主要组织相容性类 (MHC) 分子呈现 HCC 细胞表面，可以作为有效治疗的合适靶点 针对这种肿瘤的细胞介导的免疫反应。 他们假设 人类和小鼠 T 细胞库具有 AFP 肽反应性 T 细胞， 在适当的条件下可以克隆扩增和激活。 他们 提出具有三个具体目标的多管齐下的策略来测试这一点 小鼠和人类 HCC 模型的假设。